18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 603-609

  Moog, Florian ^a   Bangerter, Markus ^a   Kotzerke, Jörg ^a   Guhlmann, Albrecht ^a   Frickhofen, Norbert ^a   Reske, Sven N ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CANCER; BONE MARROW SCINTISCANNING; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; FEMALE; HODGKIN DISEASE; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0031918966     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.603     Document Type: Article

References (41)

1. Juneja SK, Wolf MM, Cooper IA: Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma. J Clin Pathol 43:630-632, 1990
2. Dick F, Bloomfield CD, Brunning RD: Incidence, cytology and histopathology of non-Hodgkin's lymphomas in the bone marrow. Cancer 33:1382-1386, 1974
3. O'Carroll DI, McKenna RW, Brunning RD: Bone marrow manifestations of Hodgkin's disease. Cancer 38:1717-1722, 1976
4. Bartl R, Frisch B, Burkhardt R, et al: Lymphoproliferations in the bone marrow: Identification and evaluation, classification and staging. J Clin Pathol 37:233-238, 1984
5. Pond GD, Castellio RA, Horning S, et al: Non-Hodgkin lymphoma: Influence of lymphography, CT, and bone marrow biopsy on staging and management. Radiology 170:159-164, 1989
6. Bartl R, Frisch B, Burkhardt R, et al: Assessment of bone marrow histology in Hodgkin's disease. Correlation with clinical factors. Br J Haematol 51:345-349, 1982
7. Rosenberg SA: Hodgkin's disease of the bone marrow. Cancer Res 31:1733-1736, 1971
8. Myers CE, Chabner BA, de Vita VT, et al: Bone marrow involvement in Hodgkin's disease: Pathology and response to MOPP chemotherapy. Blood 44:197-204, 1974
9. Specht L, Nissen NI: Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol 41:359-367, 1988
10. Munker R, Hasenclever D, Brosteanu O, et al: Bone marrow involvement in Hodgkin's disease: An analysis of 135 consecutive cases. J Clin Oncol 13:403-409, 1995
11. Ellis ME, Diehl LF, Granger E, et al: Trephine needle bone marrow biopsy in the initial staging of Hodgkin's disease: Sensitivity and specificity of the Ann Arbor staging procedure criteria. Am J Haematol 30:115-120, 1989
12. Coller BS, Chabner BA, Gralnick HR: Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphoma: Observations on the value of bilateral biopsies. Am J Pathol 3:105-119, 1977
13. Brunning RD, Bloomfield CD, McKenna RW, et al: Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med 82:365-366, 1975
14. Som P, Atkins HL, Bandoypadhyah D, et al: A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med 21:670-675, 1980
15. Larson SM, Weiden PL, Grunbaum Z, et al: Positron imaging feasibility studies. II. Characteristics of deoxyglucose uptake in rodent and canine neoplasms: Concise communication. J Nucl Med 22:875-879, 1981
16. Moog F, Bangerter M, Diederichs CG, et al: Role of whole-body FDG-PET in nodal staging of lymphoma. Radiology 203:795-800, 1997
17. Bangerter M, Kocher F, Binder T, et al: Total body positron emission tomography (PET) for staging and follow up of lymphoma. Proc Am Soc Clin Oncol, March 1995, p 387 (abstr)
18. Okada J, Yoshikawa K, Imazeki K, et al: Positron emission tomography using fluorine-18-fluorodeoxy-glucose in malignant lymphoma: A comparison with proliferative activity. J Nucl Med 33:325-329, 1992
19. Lapela M, Leskinen S, Minn H, et al: Increased glucose metabolism in untreated non-Hodgkin's lymphoma: A study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 9:3522-3527, 1995
20. Leskinen-Kallio S, Ruotsalainen U, Ngren K, et al: Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study. J Nucl Med 32:1211-1218, 1991
21. Rodriguez M, Rehn S, Ahlström H, et al: Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 36:1790-1796, 1995
22. Okada J, Yoshikawa K, Imazeki K, et al: The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis. J Nucl Med 32:686-691, 1991
23. Rosenberg SA, Berard CW, Brown BW, et al: National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical use. Cancer 49:2112-2135, 1982
24. Harnacher K, Coenen HH, Stoecklin G: Efficient stereospecific synthesis of no-carrier-added 2-(18F)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238, 1987
25. Schmidlin P. Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med 21:930-936, 1994
26. Brunning RD, McKenna RW: Bone marrow manifestation of malignant lymphoma and lymphoma-like conditions. Pathol Annu 11:1-59, 1979
27. McKenna RW, Hernandez JA: Bone marrow in malignant lymphoma. Haematol Oncol Clin North Am 2:617-635, 1988
28. Braunstein EM, White SJ: Non-Hodgkin lymphoma of bone. Radiology 135:59-63, 1980
29. Dehdashti F, Siegel BA, Griffeth LK, et al: Benign versus malignant intraosseous lesions: Discrimination by means of PET with 2-(F-18)fluoro-2-deoxy-D-glucose. Radiology 200:243-247, 1996
30. Adler LP, Blair HF, Makley JT, et al: Non-invasive grading of musculoskeletal tumors using PET. J Nucl Med 32:1508-1512, 1991
31. Wahl RL, Cody RL, Hutchins GD, et al: Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with radiolabeled glucose analogue 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 179: 765-770, 1991
32. Shreve PD, Grossman HB, Gross MD, et al: Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-(F-18)fluoro-D-glucose. Radiology 199:751-756, 1996
33. Newman JS, Francis IR, Kaminski MS, et al: Imaging of lymphoma with PET with 2-(F-18)-fluoro-2-deoxy-d-glucose: Correlation with CT. Radiology 190:111-116, 1994
34. Kubota R, Yamada S, Kubota K, et al: Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972-1980, 1992
35. Jones HA, Clark RJ, Rhodes CG, et al: In vivo measurement of neutrophil activity in experimental lung inflammation. Am J Respir Crit Care Med 149:1635-1639, 1994
36. Palmer WE, Rosenthal DI, Schoenberg OI, et al: Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-f1uoro-2-deoxy-D-glucose. Radiology 196:647-655, 1995
37. Tahara T, Ichiya Y, Kuwabara Y, et al: High [18F]-fluorodeoxyglucose uptake in abdominal abscesses: A PET study. J Comput Assist Tomogr 13:829-831, 1989
38. Guhlmann A, Storck M, Kotzerke J, et al: Lymph node staging in non-small cell lung cancer: Evaluation by [18F]-FDG positron emission tomography (PET). Thorax 52:438-441, 1997
39. Taylor IK, Hill AA, Hayes M, et al: Imaging allergen-invoked airway inflammation in atopic asthma with [18F]-fluorodeoxyglucose and positron emission tomography. Lancet 347:937-940, 1996
40. Hoffman JM, Waskin HA, Hanson MW, et al: FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 34:567-575, 1993
41. Zasadny K, Wahl RL: Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 189:847-850, 1993